Aurora kinase inhibitors: a new class of drugs targeting the regulatory mitotic system
- PMID: 20045785
- DOI: 10.1007/s12094-009-0447-2
Aurora kinase inhibitors: a new class of drugs targeting the regulatory mitotic system
Abstract
The present review gives a perspective on the Aurora kinase family members, their function in normal cells, their role in cancer progression as well as their potential as target for anticancer treatment. Mitosis has been an important target for anticancer therapy development, leading to some specific drugs mainly addressing Tubulines, as a key structure of the mitotic spindle. Vinca alkaloids, taxanes or epotilones are good examples of conventionally developed antimitotic agents. However, novel classes of antineoplastic drugs are being studied, targeting the regulatory system that controls functional aspects of mitosis, such as Aurora or Polo-like kinases or Kinespondin inhibitors. The specific role of the different Aurora kinase proteins as regulator enzymes of the mitotic process in normal cells is discussed. Some of the mechanisms that link Aurora overexpression with cancer are also considered. Thereafter, the clinical and preclinical development of the different Aurora kinase inhibitors is presented. This is nowadays a very active area of therapeutic research and at least, sixteen new compounds are being studied as potential antineoplastic drugs. Most of them are in a very early phase of clinical development. However, we summarized the most recently published findings related with these drugs: main characteristics, way of administration, dose limiting toxicities and recommended doses for further studies. Another important aspect in Aurora kinase inhibition is the study and validation of potential biomarkers to optimize the clinical development. Several studies included pharmacodynamic assessments in normal blood cells, skin or/and tumor biopsies. Several proposals included a higher mitotic index, a decreased number of mitosis with bipolar spindles or normal alignment of chromosomes and inhibition of histone H3 phosphorylation. Future strategies and challenges for trials with Aurora kinase inhibitors are also discussed.
Similar articles
-
Target validation and biomarker identification in oncology : the example of aurora kinases.Mol Diagn Ther. 2008;12(2):71-6. doi: 10.1007/BF03256272. Mol Diagn Ther. 2008. PMID: 18422371 Review.
-
Aurora-B kinase inhibitors for cancer chemotherapy.Mini Rev Med Chem. 2008 Dec;8(14):1514-25. doi: 10.2174/138955708786786480. Mini Rev Med Chem. 2008. PMID: 19075809 Review.
-
Co-inhibition of polo-like kinase 1 and Aurora kinases promotes mitotic catastrophe.Oncotarget. 2015 Apr 20;6(11):9327-40. doi: 10.18632/oncotarget.3313. Oncotarget. 2015. PMID: 25871386 Free PMC article.
-
Aurora kinase inhibitors as anticancer molecules.Biochim Biophys Acta. 2010 Oct-Dec;1799(10-12):829-39. doi: 10.1016/j.bbagrm.2010.09.004. Epub 2010 Sep 20. Biochim Biophys Acta. 2010. PMID: 20863917 Free PMC article. Review.
-
The role of Aurora-A inhibitors in cancer therapy.Ann Oncol. 2007 Jun;18 Suppl 6:vi47-52. doi: 10.1093/annonc/mdm224. Ann Oncol. 2007. PMID: 17591831 Review.
Cited by
-
Lestaurtinib inhibits histone phosphorylation and androgen-dependent gene expression in prostate cancer cells.PLoS One. 2012;7(4):e34973. doi: 10.1371/journal.pone.0034973. Epub 2012 Apr 20. PLoS One. 2012. PMID: 22532837 Free PMC article.
-
AMG 900, a potent inhibitor of aurora kinases causes pharmacodynamic changes in p-Histone H3 immunoreactivity in human tumor xenografts and proliferating mouse tissues.J Transl Med. 2014 Nov 4;12:307. doi: 10.1186/s12967-014-0307-x. J Transl Med. 2014. PMID: 25367255 Free PMC article.
-
When Just One Phosphate Is One Too Many: The Multifaceted Interplay between Myc and Kinases.Int J Mol Sci. 2023 Mar 1;24(5):4746. doi: 10.3390/ijms24054746. Int J Mol Sci. 2023. PMID: 36902175 Free PMC article. Review.
-
Mitotic Kinases and p53 Signaling.Biochem Res Int. 2012;2012:195903. doi: 10.1155/2012/195903. Epub 2012 Jul 19. Biochem Res Int. 2012. PMID: 22852086 Free PMC article.
-
Glioma pathogenesis-related protein 1 induces prostate cancer cell death through Hsc70-mediated suppression of AURKA and TPX2.Mol Oncol. 2013 Jun;7(3):484-96. doi: 10.1016/j.molonc.2012.12.005. Epub 2012 Dec 31. Mol Oncol. 2013. PMID: 23333597 Free PMC article.